Results 91 to 100 of about 395,211 (318)

Buckeye Trail Becomes Ohio's Official Hiking Trail

open access: yes, 1967
Governor James Rhodes signing a bill to make the Buckeye Trail the official hiking trail of Ohio, April 27, 1967. Pictured with Governor Rhodes (from left to right) are Kenneth D.

core  

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

A DR4, DR5 Targeting Conjugated TRAIL Treatment for Colorectal Carcinogenesis: A Way to Future? [PDF]

open access: yesPharmaceutical Sciences
TRAIL or tumor necrosis factor-related apoptosis-inducing ligand has been one of the major frontiers for the chemotherapeutic approach to treating carcinogenesis.
Parikshit Roychowdhury   +7 more
doaj   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

DESIGN OF MOTORCYLE ACTIVE CHASSIS GEOMETRY CHANGE SYSTEM

open access: yesPerner’s Contacts, 2011
Modern motorcycles have a number of electronic systems supporting their driving stability. These are usually adopted solutions used in automobiles.
Jakub Šmiraus, Michal Richtář
doaj  

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

open access: yesMolecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober   +16 more
wiley   +1 more source

Research on issues in the protection of clinical trial human subjects in China: a Delphi study

open access: yesBMC Medical Ethics
Background This study aims to identify current deficiencies in the protection of human subjects participating in clinical trials in China and propose strategies for safeguarding their rights.
Xiuqiao Yang   +9 more
doaj   +1 more source

[Leonard Arnold III]

open access: yes, 2007
Audio recording of Leonard Arnold III. Written on CD plastic: Leonard Arnold III, Leonard Arnold. 1. Working On The Line. 2. Break From The Blues. 3. Oessano. 4. Della. 5. Show Me You Nekkid. 6. Going Back To Texas. 7. Sent The Devil Packin'. 8.
Arnold, Leonard
core  

MITF maintains genome stability in nonmelanocyte lineages

open access: yesMolecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir   +13 more
wiley   +1 more source

Appalachian Trail in North Carolina

open access: yes, 2014
In 1930, the Carolina Appalachian Trail Club was organized for the purpose of completing the western North Carolina segment of the Appalachian Trail. Its home was in Asheville.
Carolina Appalachian Trail Club;
core  

Home - About - Disclaimer - Privacy